Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504153).
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00423735).
- Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DASISIONIndependent statistical analysis of the DASISION phase 3 trial of dasatinib versus imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia, including trial design, complete cytogenetic response, time-to-event analyses, statistical methodology,…
- DATAAn educational statistical analysis of the DATA phase 3 trial comparing 6 years with 3 years of adjuvant anastrozole after 2 to 3 years of tamoxifen in postmenopausal hormone-sensitive breast cancer.
- Decision Making Tool for Firearm Storage: Complete Statistical AnalysisIndependent statistical analysis of Decision Making Tool for Firearm Storage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06382194).
- Decision-aid on Breast Cancer Screening: Complete Statistical AnalysisIndependent statistical analysis of Decision-aid on Breast Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03097653).
- Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00903760).
- Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: Complete Statistical AnalysisIndependent statistical analysis of Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Complete Statistical AnalysisIndependent statistical analysis of Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: primary endpoint results, effect estimate…
- Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- DESKTOP IIIAn independent statistical analysis of DESKTOP III, a randomized study comparing tumor debulking surgery versus chemotherapy alone in recurrent platinum-sensitive ovarian cancer.
- DESTINY-Breast04Independent statistical analysis of DESTINY-Breast04, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's choice for HER2-low breast cancer. Includes the reported progression-free survival analysis, trial design, statistical methodology, interpretation, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- DESTINY-Breast07Independent statistical analysis of DESTINY-Breast07, a phase 1/2 randomized study of trastuzumab deruxtecan combinations in HER2-positive metastatic breast cancer, including trial design, registered endpoints, planned statistical analysis, and interpretation.
- DESTINY-Breast09Independent statistical analysis of DESTINY-Breast09, the phase 3 randomized trial of trastuzumab deruxtecan with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer.
- DESTINY-CRC01Independent statistical analysis of DESTINY-CRC01, a phase 2 sequential study of DS-8201a in HER2-expressing advanced colorectal cancer, including trial design, response endpoints, planned statistical interpretation, and safety.
- DESTINY-CRC02Independent statistical analysis of DESTINY-CRC02, a randomized phase 2 trial of trastuzumab deruxtecan in participants with HER2-overexpressing advanced or metastatic colorectal cancer, including its design, objective response endpoint, statistical methodology, safety, and…
- DESTINY-Gastric02A detailed statistical analysis and educational interpretation of DESTINY-Gastric02, a phase 2 single-group trial of trastuzumab deruxtecan in HER2-positive unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma.
- DESTINY-Gastric04An educational statistical analysis of DESTINY-Gastric04, a randomized phase 3 trial comparing trastuzumab deruxtecan with ramucirumab plus paclitaxel in HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma after progression on or after a…
- DESTINY-Lung03An independent statistical analysis of DESTINY-Lung03, a randomized phase Ib study evaluating the safety of T-DXd and immunotherapy agents with and without chemotherapy in advanced or metastatic HER2+, non-squamous NSCLC.
- DESTINY-PanTumor02A detailed statistical analysis of DESTINY-PanTumor02, a phase 2 non-randomized study of trastuzumab deruxtecan in patients with selected HER2-expressing tumors, including trial design, objective response rate methodology, planned analysis, and statistical interpretation.
- Detection of Barrett s Esophagus in Patients Without GERD Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Detection of Barrett s Esophagus in Patients Without GERD Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04880044).
- Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG: Complete Statistical AnalysisIndependent statistical analysis of Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Developing and Validating Fertilit-e: Complete Statistical AnalysisIndependent statistical analysis of Developing and Validating Fertilit-e: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03599661).
- Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Development of Vitamin D as a Therapy for Breast Cancer – Phase 2: Complete Statistical AnalysisIndependent statistical analysis of Development of Vitamin D as a Therapy for Breast Cancer - Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DFCI 10-106Independent statistical analysis of Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid: Complete Statistical AnalysisIndependent statistical analysis of Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01165996).
- DIGESTIndependent statistical analysis of Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01285557).
- Disposable Powered Articulating Linear Cutter Stapler in Total-Thoracoscopic Anatomic Lobectomy (Segmentectomy): Complete Statistical AnalysisIndependent statistical analysis of Disposable Powered Articulating Linear Cutter Stapler in Total-Thoracoscopic Anatomic Lobectomy (Segmentectomy): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- DKP 3M SCIndependent statistical analysis of Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- DOC-MEKIndependent statistical analysis of Docetaxel With or Without AZD6244 in Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01256359).
- Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01382706).
- Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett’s Esophagus Following Ablation?: Complete Statistical AnalysisIndependent statistical analysis of Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning…